Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the ...

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, ...

The results from Krascendo 170 support further development of divarasib plus pembrolizumab as a chemotherapy-free first-line ...

Results from a study on an investigational combination treatment for patients with advanced KRAS G12C+ non-small cell lung ...

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone ...

Phase 3 ROADS enrolled 204 patients across 32 centers (2021–2025) with 2–7 cm brain metastases, comparing tile-based intraoperative radiation versus external stereotactic radiation. Surgical bed ...

For-profit companies now dominate hospice care in the U.S., and private equity firms are moving in. Some say the trend reflects the underlying economics and need for scale. Like all things in ...

The pan-RAS inhibitor met primary end points of overall survival and progression-free survival as a second-line therapy for patients with metastatic pancreatic cancer. An open-label, phase 3 trial of ...

Treatment after treatment for second-line treatment for pancreatic cancer has failed in clinical trials. Daraxonrasib seems to have broken the losing streak, says MD Anderson's Shubman Pant, M.D., M.B ...

Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up. At ...

The second-line drug for metastatic pancreatic cancer is pan-RAS inhibitor that recruits cyclophilin A to stick to RAS proteins, explains Subham Pant, M.D., M.B.B.S., of The University of Texas MD ...